CN103347499B - 通过错流过滤进行的液体介质交换在制备药物混悬液中的用途 - Google Patents

通过错流过滤进行的液体介质交换在制备药物混悬液中的用途 Download PDF

Info

Publication number
CN103347499B
CN103347499B CN201280005390.0A CN201280005390A CN103347499B CN 103347499 B CN103347499 B CN 103347499B CN 201280005390 A CN201280005390 A CN 201280005390A CN 103347499 B CN103347499 B CN 103347499B
Authority
CN
China
Prior art keywords
suspension
liquid medium
diafiltration
drug
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280005390.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN103347499A (zh
Inventor
H·P·尼伊德曼恩
H·博特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Publication of CN103347499A publication Critical patent/CN103347499A/zh
Application granted granted Critical
Publication of CN103347499B publication Critical patent/CN103347499B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
CN201280005390.0A 2011-01-12 2012-01-11 通过错流过滤进行的液体介质交换在制备药物混悬液中的用途 Active CN103347499B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161431942P 2011-01-12 2011-01-12
US61/431,942 2011-01-12
PCT/EP2012/050336 WO2012095439A1 (en) 2011-01-12 2012-01-11 Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions

Publications (2)

Publication Number Publication Date
CN103347499A CN103347499A (zh) 2013-10-09
CN103347499B true CN103347499B (zh) 2017-04-05

Family

ID=45478323

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280005390.0A Active CN103347499B (zh) 2011-01-12 2012-01-11 通过错流过滤进行的液体介质交换在制备药物混悬液中的用途

Country Status (10)

Country Link
US (1) US9066864B2 (cg-RX-API-DMAC10.html)
EP (1) EP2663287A1 (cg-RX-API-DMAC10.html)
JP (1) JP5934719B2 (cg-RX-API-DMAC10.html)
CN (1) CN103347499B (cg-RX-API-DMAC10.html)
AU (1) AU2012206621B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013016851B1 (cg-RX-API-DMAC10.html)
CA (1) CA2823972C (cg-RX-API-DMAC10.html)
MX (1) MX346749B (cg-RX-API-DMAC10.html)
SG (2) SG10201807631SA (cg-RX-API-DMAC10.html)
WO (1) WO2012095439A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6478959B2 (ja) * 2016-09-07 2019-03-06 株式会社富士薬品 粒子含有組成物を製造するためのシステム及び方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1705483A (zh) * 2002-10-25 2005-12-07 阿克佐诺贝尔公司 延长释放的药物组合物
CN1735403A (zh) * 2002-12-18 2006-02-15 奇斯药制品公司 用于吸入的含有微粒化结晶活性组分的无菌含水悬浮液的制备

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4790912B2 (ja) 1999-05-12 2011-10-12 メタボリックス，インコーポレイテッド ポリヒドロキシアルカノエートを精製するための方法
EP1225968B1 (en) 1999-09-17 2006-04-05 Alfa Laval Nakskov A/S A method and an apparatus for continuous cross-flow diafiltration
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
WO2003055469A1 (en) * 2001-12-21 2003-07-10 Celator Technologies Inc. Improved polymer-lipid delivery vehicles
WO2003063877A1 (en) * 2002-02-01 2003-08-07 Akzo Nobel N.V. Cefquinome composition for intra-mammary administration in cattle
CN102811743B (zh) * 2009-12-11 2015-11-25 佰恩德治疗股份有限公司 冻干治疗颗粒的稳定制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1705483A (zh) * 2002-10-25 2005-12-07 阿克佐诺贝尔公司 延长释放的药物组合物
CN1735403A (zh) * 2002-12-18 2006-02-15 奇斯药制品公司 用于吸入的含有微粒化结晶活性组分的无菌含水悬浮液的制备

Also Published As

Publication number Publication date
US9066864B2 (en) 2015-06-30
CA2823972C (en) 2019-05-28
MX346749B (es) 2017-03-29
WO2012095439A1 (en) 2012-07-19
SG191963A1 (en) 2013-08-30
JP2014502624A (ja) 2014-02-03
US20130281425A1 (en) 2013-10-24
SG10201807631SA (en) 2018-10-30
EP2663287A1 (en) 2013-11-20
AU2012206621B2 (en) 2017-04-27
MX2013008118A (es) 2013-08-12
CN103347499A (zh) 2013-10-09
BR112013016851B1 (pt) 2021-08-31
CA2823972A1 (en) 2012-07-19
BR112013016851A2 (pt) 2016-10-04
AU2012206621A1 (en) 2013-07-04
JP5934719B2 (ja) 2016-06-15

Similar Documents

Publication Publication Date Title
JP7203078B2 (ja) 粒子の連続製造方法
CN1259902C (zh) 制造紫杉醇和白蛋白的纳米颗粒的方法
CN102149410B (zh) 医疗用复合有机化合物粉体及其制造方法以及悬浮液
AU2008256681B2 (en) Compositions comprising high concentration of biologically active molecules and processes for preparing the same
EP1438023B1 (en) Process for preparing crystalline particles of fluticasone, beclomethasone, salmeterol and salbutamol
JP5160702B2 (ja) 脂質ブレンドを含むリン脂質懸濁液の調製
WO2013144554A1 (en) Production of near monodisperse particles using milling and membrane separation.
NZ250116A (en) Preventing particle aggregation using adsorbed polymeric surfactant surface modifiers
CN1780670A (zh) 反溶剂凝固方法
BRPI0510754B1 (pt) processo para preparação de um isolado de proteína
CN1564677A (zh) 含有水不溶性的稳定纳米颗粒和赋形剂如中链甘油三酯(mct)的水性分散体
CN103347499A (zh) 通过错流过滤进行的液体介质交换在制备药物混悬液中的用途
Onesti et al. Continuous tangential flow filtration to isolate extracellular vesicles from dairy by-products
JP2023502412A5 (cg-RX-API-DMAC10.html)
Bergillos-Ruiz et al. Impact of carrier particle surface properties on drug nanoparticle attachment
CN107049963B (zh) 一种西罗莫司纳米药物组合物及其制备方法
JPWO2014129614A1 (ja) 経口投与用吸着剤並びに腎疾患治療剤及び肝疾患治療剤
CN113559061A (zh) 氟比洛芬酯脂肪乳注射液生产工艺
Markad et al. Review on: Solubility enhancement of poorly water soluble drugs
WO2012095438A1 (en) Particles and suspensions of cephalosporin antibiotics
CN105477001B (zh) 一种积雪草酸氨丁三醇盐脂质纳米粒制剂及其制备方法
Yamashita et al. A hydrophobic peptide fraction that enhances the water dispersibility of curcumin
CN115403481A (zh) 一种通过离子交换树脂纯化碘海醇的方法
JP2000327562A (ja) リボフラビンを含む噴霧顆粒の製造方法
BR112020023958A2 (pt) aparelho de bobina de lise, e, método para lisar células.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant